Evidence map›Paper›PMID 36503412›Full record

ArticleLeukemia & lymphoma2023

Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection.

Kurt S Bantilan, Neil E Kay, Sameer A Parikh, Kari G Rabe, Timothy G Call, Jose F Leis, Wei Ding, Susan L Slager, Jacob D Soumerai, Lindsey E Roeker and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kurt S BantilanMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-8771-721X
Neil E KayMayo Clinic College of Medicine, Rochester, MN, USA.
Sameer A ParikhMayo Clinic College of Medicine, Rochester, MN, USA.ORCID 0000-0002-3221-7314
Kari G RabeMayo Clinic College of Medicine, Rochester, MN, USA.
Timothy G CallMayo Clinic College of Medicine, Rochester, MN, USA.
Jose F LeisMayo Clinic College of Medicine, Scottsdale, AZ, USA.
Wei DingMayo Clinic College of Medicine, Rochester, MN, USA.
Susan L SlagerMayo Clinic College of Medicine, Rochester, MN, USA.
Jacob D SoumeraiMassachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID 0000-0002-3062-6819
Lindsey E RoekerMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Anthony MatoMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrew D ZelenetzMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1403-6883

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Translating Stress Response Targeted Therapy for B-Cell LymphomasP50CA192937 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DALLA-FAVERA, RICCARDO, ZELENETZ, ANDREW D. · 2016 to 2020
$10.9M
Prevalence, etiology, and clinical implications of low count monoclonal B-cell lymphocytosis (MBL)R01AG058266 · NIA · MAYO CLINIC ROCHESTER · PI SHANAFELT, TAIT D, SLAGER, SUSAN L · 2018 to 2022
$3.2M
Predicting Clinical Outcome After Traditional and Ibrutinib-based Therapy In Chronic Lymphocytic LeukemiaR01CA193541 · NCI · MAYO CLINIC ROCHESTER · PI KAY, NEIL E, SHANAFELT, TAIT D · 2015 to 2019
$2.9M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA192937NCI NIH HHS R01 CA193541NIA NIH HHS R01 AG058266
6 · The paper itself

Abstract

Targeted therapies have largely replaced chemoimmunotherapy (CIT) in first-line treatment of chronic lymphocytic leukemia (CLL). We aimed to develop a prognostic model to determine who would benefit from first-line CIT vs target therapy. In follicular lymphoma, time from diagnosis to second treatment (TT2T) correlates better with overall survival (OS) than time from diagnosis to first treatment (TT1T). We hypothesized that TT2T is a potential surrogate for OS in CLL. In a model-building cohort (

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellHumansPrognosisRisk FactorschemoimmunotherapyChronic lymphocytic leukemianon-Hodgkin lymphomaprognostic modelsurvivaltargeted therapy

Identifiers

PMID36503412
PMCPMC10629364

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.